We are live on ! Find out more

Becton Dickinson

BDX

Market cap $52B

190.74 USD

-1.26

0.66%

At close Updated Aug 24, 4:00 PM EDT

Pre-market

After hours

190.74

0.00

0%

1 day

-0.66%

5 days

3.14%

1 month

21.99%

3 months

29.1%

6 months

4.52%

Year to date

-2.15%

1 year

-2.01%

5 years

-21.12%

10 years

12.85%

About: Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Employees: 72,000

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.5%

Neutral 48.5%

Negative 6.1%

Best Dividend Kings: August 2026

Dividend Kings are outperforming the S&P 500 YTD, with a 14.98% total return versus SPY's 12.89%. Thirty Dividend Kings are beating SPY, and 25 appear both potentially undervalued and offer ≥10% annualized return potential. Dividend growth among Kings accelerated, with the average rate rising to 4.12% and several notable increases announced.

Best Dividend Kings: August 2026

Zacks Investment Research

BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

Zacks Investment Research

Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.

Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.

Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

24/7 Wall Street

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

Becton, Dickinson and Company Q3 Earnings Call Highlights

Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.

Becton, Dickinson and Company Q3 Earnings Call Highlights

Zacks Investment Research

BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down

BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.

BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down

Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™